Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
A pilot study investigating antitumorigenic potential of topical itraconazole in the treatment of basal cell carcinoma
Protocol Number:
J1299
Phase:
Pilot
Physician:
Timothy Wang
Purpose:
This research is being done to study the molecular effects of topically applied itraconazole ointment on the growth of basal cell carcinomas.
Eligibility:
People over 18 years of age who have been diagnosed with basal cell carcinoma by their doctor and who are awaiting surgery may join the study.
Treatment:
Basal cell carcinoma is the most common type of skin cancer in Caucasians worldwide. Although rarely metastatic, it can be locally destructive causing disfigurement and pain. Current therapies include surgical removal, local destruction, radiotherapy and others. Advances in understanding the molecular basis behind BCCs indicate that mutations in the hedgehog signaling pathway can lead to the development of many sporadically occurring BCCs. An oral drug that targets the hedgehog signaling pathway has been shown to be effective in treating patients with metastatic and inoperable BCCs. There is evidence that itraconazole, a commonly prescribed antifungal medication may also affect this pathway. It is not known whether itraconazole ointment applied topically can affect the growth of BCCs.
Population:
Adult
Last Update
09/20/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer